Engimmune Therapeutics Announces the Appointment of Dr Annalisa D’Andrea to its Board of Directors

Leading industry expert with more than 25 years of experience in translation research in immunology BASEL, Switzerland, May 23, 2023 /PRNewswire/ — Engimmune Therapeutics AG (“Engimmune”), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D’Andrea to its board of directors as a non-executive director … Read more

CORVIA MEDICAL PUBLIE LES RÉSULTATS D’UN ESSAI CLINIQUE DE DEUX ANS CONFIRMANT LE BÉNÉFICE DURABLE ET LA SÉCURITÉ DE SON SHUNT AURICULAIRE CHEZ LES PATIENTS SOUFFRANT D’INSUFFISANCE CARDIAQUE USA – Français USA – español USA – Deutsch

LE PREMIER ESSAI CONTRÔLÉ RANDOMISÉ DE PHASE III SUR LA THÉRAPIE DE SHUNT AURICULAIRE RESTE PROMETTEUR TEWKSBURY, Massachusetts, 23 mai 2023 /PRNewswire/ — Corvia Medical, Inc, une société dédiée à la transformation du traitement de l’insuffisance cardiaque, a annoncé aujourd’hui les résultats à deux ans de son essai clinique randomisé REDUCE LAP-HF II, confirmant l’innocuité et l’efficacité soutenue du … Read more

Scarlet Therapeutics Announces Seed Financing to Advance Development of Therapeutic Red Blood Cell Platform

Pioneering platform to generate novel therapies with potential to treat a wide range of diseases Financing led by Science Creates Ventures and Meltwind to fund development of the platform and initial product candidates BRISTOL, England, May 23, 2023 /PRNewswire/ — Scarlet Therapeutics (“Scarlet”), a leader in red blood cell-based therapeutics, announces today that it has … Read more

A.Menarini Diagnostics oznamuje spustenie platformy PRIME MDx

FLORENCIA, Taliansko, 23. mája 2023 /PRNewswire/ — Spoločnosť A.Menarini Diagnostics S.r.l. s potešením oznamuje komerčné spustenie svojej platformy PRIME MDx: plne automatizovanej platformy molekulárnej diagnostiky od vzoriek k výsledkom, ktorá obsahuje všetko v jednom, na spracovanie rôznych testovacích portfólií prostredníctvom PCR v reálnom čase. Pandémia Covid-19 výrazne pretvorila trh molekulárnej diagnostiky a posunula ju smerom k bezproblémovej automatizácii, … Read more

A.Menarini Diagnostics сообщает о выпуске платформы PRIME MDx

ФЛОРЕНЦИЯ, Италия, 23 мая 2023 г. /PRNewswire/ — Компания A.Menarini Diagnostics S.r.l. сообщает о коммерческом запуске своей платформы PRIME MDx, которая представляет собой универсальную, полностью автоматизированную платформу молекулярной диагностики для обработки различных тестов с использованием метода ПЦР в режиме реального времени. Пандемия COVID-19 значительно изменила рынок молекулярной диагностики, продвигая его в направлении бесперебойной автоматизации, простоты использования, … Read more

Suvoda annonce la disponibilité générale d’une nouvelle solution eCOA puissante

Suvoda comble les lacunes des solutions eCOA traditionnelles, en rationalisant et en simplifiant la licence, la localisation et la conception des questionnaires pour un déploiement plus rapide PHILADELPHIE, 23 mai 2023 /PRNewswire/ — Suvoda LLC, une entreprise mondiale de technologie d’essais cliniques spécialisée dans les études complexes dans des domaines thérapeutiques tels que l’oncologie, le … Read more

OMRON Healthcare Celebrates 50 Years of Blood Pressure Monitor History

KYOTO, Japan, May 23, 2023 /PRNewswire/ — OMRON Healthcare Co., Ltd. (hereinafter referred to as the Company) based in Muko City, Kyoto Prefecture, Japan, is proud to announce the celebration of its 50th anniversary in blood pressure monitor production this year. Since the introduction of its first manual and manometer-type blood pressure monitor in 1973, … Read more

Suvoda kündigt die allgemeine Verfügbarkeit der leistungsstarken neuen eCOA-Lösung an

Suvoda füllt Lücken in herkömmlichen eCOA-Lösungen und rationalisiert und vereinfacht die Lizenzierung, Lokalisierung und das Design von Fragebögen für eine schnellere Bereitstellung PHILADELPHIA, 23. Mai 2023 /PRNewswire/ — Suvoda LLC, ein globales Technologieunternehmen für klinische Studien, das sich auf komplexe Studien in therapeutischen Bereichen wie Onkologie, zentrales Nervensystem (ZNS) und seltene Krankheiten spezialisiert hat, gab … Read more

Kindred Group utilises authorisation to repurchase own shares

VALLETTA, Malta, May 23, 2023 /PRNewswire/ — Kindred Group’s Board of Directors has decided to start exercising the buy-back mandate received at the Extraordinary General Meeting on 17 May 2023. Share repurchases may take place during the period between 23 May 2023 and 22 June 2023. The Board of Directors of Kindred Group plc (“Kindred” or … Read more